Table 1.
Gene Symbol | Gene Description | Role in RNA Modification | Expression | Biological Function | Mechanism | Reference |
---|---|---|---|---|---|---|
METTL3 | Methyltransferase-like 3 | m6A writer | Elevated or decreased (controversial) | Maintains or prevents stemness of GSSs; transforms or reverse malignancy; enhances radiosensitivity; reduces migration and induces apoptosis (controversial) | Installs m6A marks in GSCs-specifically-expressed genes, such as SOX2; modulates ADAR1 and APOBEC3A to induce A-to I and C-to-U editing; upregulates BCL-X and NCOR2 to affect the levels of SRSFs; prevents YTHDC1-dependent NMD; introduces m6A modifications in critical factors, such as ADAM19; downregulates HSP70 expression | [56,57,58,59,60] |
METTL14 | Methyltransferase-like 14 | m6A writer | Elevated or Decreased (controversial) | Prevents growth, self-renewal, and tumorigenesis of GSCs | Introduces m6A modifications in critical factors, such as ADAM19 | [58,59] |
WTAP | Wilms’ tumor 1-associated protein | m6A writer | Elevated | Stimulates tumorigecity, migration and invasion and inhibits apoptosis | Increases EGFR expression; | [58,61,62,63] |
VIRMA/KIAA1429 | Virilizer like m6A methyltransferase associated protein | m6A writer | Decreased | - | - | [58] |
ZC3H13/KIAA0853/Flacc | Zinc finger CCCH domain-containing protein 13 | m6A writer | Decreased | Inhibits malignant tansformation and reduces chemosensitivity | - | [58] |
RBM15 | RNA binding motif protein 15 | m6A writer | Elevated | - | - | [58] |
RBM15B | RNA binding motif protein 15B | m6A writer | Elevated | - | - | [58] |
FTO | Fat mass and obesity-associated protein | m6A and m6Am eraser | Decreased or elevated (controversial) | Promotes self-renewal ability and tumorigenecity of GSCs | Maintains the stability of c-Myc and CEBPA transcripts | [58,59,64] |
ALKBH5 | α-Ketoglutarate-dependent dioxygenase alkB homolog 5 | m6A eraser | Elevated | Inhibits cell proliferation of GSCs | Demethylates FOXM1 nascent transcripts to enhance its expression by the aid of lncRNA FOXM1-AS | [58,65] |
YTHDF1 | YTH N6-methyladenosine RNA binding protein 1 | m6A reader | Elevated | - | - | [58] |
YTHDF2 | YTH N6-methyladenosine RNA binding protein 2 | m6A reader | Elevated | - | - | [58] |
YTHDF3 | YTH N6-methyladenosine RNA binding protein 3 | m6A reader | Elevated | - | - | [58] |
YTHDC1 | YTH domain-containing 1 | m6A reader | - | Maintains stemness of GSCs | - | [57] |
YTHDC2 | YTH domain-containing 2 | m6A reader | Elevated in LGGs; decreased in GBM | - | - | [58] |
IGF2BP1/IMP1 | Insulin like growth factor 2 mRNA binding protein 1 | m6A reader | Elevated | Promotes cell proliferation and invasion | Stabilizes the mRNA transcripts of its target genes, including c-Myc, MKI67, PTEN and CD44 | [66,67]. |
IGF2BP2/IMP2 | Insulin like growth factor 2 mRNA binding protein 2 | m6A reader | Elevated | Promotes cell proliferation, migration, invasion and EMT; sensitizes GBM to TMZ treatment; maintains stemness of GSCs; promotes OXPHOS; promotes hypoxia-dependent molecular reprogramming | Activates IGF2-mediated PI3K/AKT signaling; binds to let-7 MREs and prevents LIN28-independent let-7 target gene silencing, including HMGA1, HMGA2, CCND2 and RRM2; binds to several mRNAs such as COX7B, NDUS7, NDUF3 and NDUFS3; interacts with HIF1A-AS2 to maintain HMGA1 expression | [68,69,70,71] |
IGF2BP3/IMP3 | Insulin like growth factor 2 mRNA binding protein 3 | m6A reader | Elevated | Promotes cell proliferation, anchorage-independent growth, invasion, EMT and chemoresistance | Activates PI3K/MAPK via promoting IGF2 translation; enhances translation of p65 (RELA) | |
eIF3b | Eukaryotic translation initiation factor 3 subunit b | m6A reader | Dcreased | Inhibits cell proliferation and induces G0/G1 cell cycle arrest and apoptosis | - | [72] |
eIF3h | Eukaryotic translation initiation factor 3 subunit h | m6A reader | Dublicated | - | - | [73] |
hnRNPA2B1 | Heterogeneous nuclear ribonucleoprotein A2/B1 | m6A reader | Elevated | Promotes GBM cell viability, adhesion, migration, invasion, chemoresistance to TMZ and tumorigenecity as well as protects cells from apoptosis and reactive oxygen species (ROS) generation | Interacts with SOX2; downregulates tumor suppressors such as c-FLIP, BIN1 and WWOX, and upregulates phospho-STAT3, MMP-2, and the proto-oncogene RON | [58,74,75] |
hnRNPC | Heterogeneous nuclear ribonucleoprotein C | m6A reader | Elevated in LGGs but decreased in GBM | Promotes migratory and invasive activities, increases cell proliferation and protects GBM cells from etoposide-induced apoptosis | Interacts with SOX2; binds directly to pri-mir-21 and promotes the processing of miR-21 that targets PDCD4, supporting Akt and p70S6K activation, | [58,76] |
METTL4 | Methyltransferase-like 4 | m6Am writer | Missensely mutated | - | - | [77] |
DCP2 | Decapping mRNA 2 | m6Am reader | Participates in radiosensitivity and DNA damage response | - | [78] | |
TRMT6/TRM6 | tRNA methyltransferase 6 | m1A writer | Elevated | - | - | [79] |
TRMT61A/TRM61A | tRNA methyltransferase 61A | m1A writer | Elevated | - | - | [79] |
ALKBH1 | α-Ketoglutarate-dependent dioxygenase alkB homolog 1 | m1A eraser | Elevated | Promotes cell proliferation and tumorigenecity | Induces DNA demethylation on hypoxia response genes, | [80] |
NSUN5 | NOP2/Sun RNA methyltransferase 5 | m5C writer | Decreased | Leads to an adaptive translational program for survival under cellular stress and renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1 | Drives an overall depletion of protein synthesis | [81,82] |
LYREF | Aly/REF export factor | m5C reader | Elevated | - | - | [83,84] |
TET1 | Tet methylcytosine dioxygenase 1 | hm5C writer | Elevated | - | - | [85] |
TET2 | Tet methylcytosine dioxygenase 2 | hm5C writer | Decreased | - | - | [86] |
TET3 | Tet methylcytosine dioxygenase 3 | hm5C writer | Decreased | - | - | [87] |
ADAR1/ADAR | Adenosine deaminase RNA specific 1 | I writer | Decreased | Inhibits cell proliferation | Downregulates A-to-I RNA editing | [88] |
ADAR2/ADARB1 | Adenosine deaminase RNA specific 2 | I writer | Decreased | Inhibits cell proliferation | Downregulates A-to-I RNA editing in the pre-mRNA of a phosphatase CDC14B, thereby downregulates Skp2/p21/p27 proteins | [88,89,90] |
ADAR3/ADARB2 | Adenosine deaminase RNA specific 3 | I writer | Decreased | - | - | [88] |
DKC1 | Dyskerin pseudouridine synthase 1 | ψ writer | Elevated | Promotes cell growth by stimulating cell cycle progression and activates migration | Upregulates N-cadherin, HIF1A, and MMP-2 expression | [91] |
Modification abbreviations: A-to-I, adenosine-to-inosine; C-to-U, cytidine to uridine, m1A, N1-methyladenosine; m5C, 5-methylcytosine; m6A, N6-methyladenosine; m6Am, N6, 2′O-dimethyladenosine; hm5C, 5-hydroxymethylcytosine; I, inosine; ψ, pseudouridine. Others: ADAM19, a disintegrin and metallopeptidase domain 19; ADAR1,adenosine deaminase RNA specific 1; APOBEC3A, apolipoprotein B mRNA editing enzyme catalytic subunit 3A; BCL-X, Bcl-2-like protein 1, BCL2L1; BIN1, bridging integrator 1; c-FLIP, cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein; c-Myc, avian myelocytomatosis viral oncogene homolog; CCND2, cyclin D2; CDC14B, cell division cycle 14B; CEBPA, CCAAT enhancer binding protein alpha; COX7B, mitochondrial cytochrome c oxidase subunit 7B; EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; FOXM1, forkhead box M1; FOXM1-AS, forkhead box M1-antisense RNA; GBM, glioblastoma; GSCs, glioma stem-like cells; HIF1A, hypoxia-inducible factor 1 alpha; HIF1A-AS2, hypoxia-inducible factor 1 alpha-antisense RNA 2; HMGA1/2, high mobility group AT-hook 1/2; HSP70, heat shock protein 70; IGF2, insulin-like growth factor 2; LGG, low-grade glioma; MAPK, mitogen-activated protein kinase; MKI67, marker of proliferation Ki-67; MMP-2, matrix metallopeptidase 2; MRE, miRNA recognition element; NCOR2, nuclear receptor corepressor 2; NDUF3,NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3; NDUFS3, mitochondrial NADH dehydrogenase [ubiquinone] iron-sulfur protein 3; NDUS7, NADH dehydrogenase iron-sulfur protein 7; NMD, nonsense-mediated mRNA decay; NQO1, Quaking gene isoform 6; OXPHOS, oxidative phosphorylation; p70S6K, p70 S6 kinase; PDCD4, programmed cell death 4; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; RON, macrophage stimulating 1 receptor, MST1R; RRM2, ribonucleotide reductase regulatory subunit M2; Skp2, S-phase kinase associated protein 2; SOX2, SRY-box transcription factor 2; STAT3, signal transducer and activator of transcription 3; TMZ, temozolomide; WWOX, WW domain containing oxidoreductase.